Boztas Ali O, Karakuzu Ozgur, Galante Gabriela, Ugur Zafer, Kocabas Fatih, Altuntas Cengiz Z, Yazaydin A Ozgur
Texas Institute of Biotechnology Education and Research , 10555 Stella Link Road, Houston, Texas, 77025, United States.
Mol Pharm. 2013 Jul 1;10(7):2676-83. doi: 10.1021/mp400101k. Epub 2013 Jun 13.
The use of cytotoxic chemotherapic agents is the most common method for the treatment of metastatic cancers. Poor water solubility and low efficiency of chemotherapic agents are among the major hurdles of effective chemotherapy treatments. Curcumin and paclitaxel are well-known chemotherapic agents with poor water solubility and undesired side effects. In this study, a novel drug nanocarrier system was formulated by encapsulating curcumin and paclitaxel in poly(β-cyclodextrin triazine) (PCDT) for the therapy of four cancer models; ovarian, lung, prostate, and breast cancer. Cell viability and colony formation assays revealed enhanced curcumin cytotoxicity upon complexation. Annexin V apoptotic studies showed that the PCDT complexation improved curcumin induced apoptosis in human ovarian cancer cell lines A2780 and SKOV-3, human nonsmall cell lung carcinoma cell line H1299, and human prostate cancer line DU-145, while no significant effect was observed with paclitaxel/PCDT complexation. The bioactivity of combining curcumin and paclitaxel was also investigated. A synergism was found between curcumin and paclitaxel, particularly when complexed with PCDT on A2780, SKOV-3, and H1299 cancer cell lines.
使用细胞毒性化疗药物是治疗转移性癌症最常见的方法。化疗药物的水溶性差和效率低是有效化疗治疗的主要障碍。姜黄素和紫杉醇是众所周知的水溶性差且有不良副作用的化疗药物。在本研究中，通过将姜黄素和紫杉醇包裹在聚（β-环糊精三嗪）（PCDT）中制备了一种新型药物纳米载体系统，用于治疗四种癌症模型；卵巢癌、肺癌、前列腺癌和乳腺癌。细胞活力和集落形成试验表明，络合后姜黄素的细胞毒性增强。膜联蛋白V凋亡研究表明，PCDT络合改善了姜黄素诱导人卵巢癌细胞系A2780和SKOV-3、人非小细胞肺癌细胞系H1299和人前列腺癌细胞系DU-145的凋亡，而紫杉醇/PCDT络合未观察到显著效果。还研究了姜黄素和紫杉醇联合使用的生物活性。发现姜黄素和紫杉醇之间存在协同作用，特别是在A2780、SKOV-3和H1299癌细胞系上与PCDT络合时。
